Compare Capital One Financial Corp. (COF) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capital One Financial Corp. vs TG Therapeutics Inc — how do they compare? Capital One Financial Corp. trades at $222.77 (market cap $134.45B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Capital One Financial Corp. is far larger — about 17.6× TG Therapeutics Inc's market cap, and Capital One Financial Corp. pays a 1.46% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| COF | TGTX | |
|---|---|---|
Market Cap | $134.45B | $7.64B |
Sector | Financials | Health |
52-Week High | $257.94 | $59.06 |
52-Week Low | $176.10 | $26.94 |
Dividend Yield | 1.46% | — |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Capital One Financial (COF) trades at $223.09, up 1.88% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 12.07 and P/B of 1.18, while Q2 2026 earnings beat expectations. Recent news highlights the Discover integration progress and a 20-year arena naming rights extension, reinforcing brand commitment.
The outlook is positive with a consensus price target of $251.60, implying 13% upside, supported by 63% analyst buy ratings. Key risks include integration execution of Discover, credit loss provisions, and macroeconomic sensitivity. Revenue growth to $62.0B in 2026 projects a net income margin rebound to 16.96%, offering a compelling value proposition if synergies materialize.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Capital One Financial Corp.
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
